PDS Biotechnology, based in Princeton, New Jersey, develops clinical-stage immunotherapies for various cancers, including its lead product PDS0101, which targets HPV16. The company went public on October 1, 2015, and has 25 employees.
PDSB filed a patent for "t cell activating immunotherapeutic for treatment of mucin 1 protein expressing human cancers" on Thu, October 19, 2023. The patent was officially published on Thu, September 26, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
